Thrivent Financial for Lutherans
ALNY icon

Thrivent Financial for Lutherans’s Alnylam Pharmaceuticals ALNY Stock Holding History

Thrivent Financial for Lutherans’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-20,470
Closed -$6.77M – 2594
2026
Q1 		$6.77M Sell
20,470
-171
-0.8% -$58.2K 0.01% 784
2025
Q4 		$8.21M Buy
+20,641
New +$9.13M 0.01% 744
2023
Q2 		– Sell
-1,049
Closed -$210K – 2460
2023
Q1 		$210K Hold
1,049
– – ﹤0.01% 2376
2022
Q4 		$249K Buy
+1,049
New +$224K ﹤0.01% 2298

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Thrivent Financial for Lutherans's ALNY Position: Q2 2026 in Review

Thrivent Financial for Lutherans sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2026, closing a stake of 20,470 shares — an estimated $6.77M sold.

Thrivent Financial for Lutherans first reported a position in ALNY in Q4 2022 and held it in 4 quarters. The position peaked at $8.21M in Q4 2025. 790 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Thrivent Financial for Lutherans reported no remaining Alnylam Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 20,470 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $6.77M.
  • Thrivent Financial for Lutherans first reported a position in Alnylam Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • Thrivent Financial for Lutherans's Alnylam Pharmaceuticals position peaked at $8.21M in Q4 2025.
  • 790 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.